Kyverna Therapeutics, Inc. Stock: price and insider trades · United States

Kyverna Therapeutics, Inc. is a Health Care company. Its directors and officers file their transactions with SEC (Form 4). Between 23 October 2025 and 23 October 2026, 11 insiders published 13 filings.

On the market, 1 insider bought (1 purchase totalling €852k) while 1 insider sold (1 sale totalling €249k). Purchases outweigh sales by €602k. Open-market purchases are the filings investors watch most closely, because the insider pays for the shares out of pocket. One trade stands out by size: a purchase of €852k from Seidenberg Beth C, disclosed on 22 December 2025. The buyers include 1 senior executive.

Compared with its exchange (3,167 companies, median 24 filings), a count of 13 filings is below the norm. Looking back to 2024, when coverage begins, insiders filed 5 purchases and 1 sale. For the fiscal year to 31 December 2025, the annual 10-K puts net income at -161.3 m USD.

In the case of 1 purchase, another manager of the company was buying within the same 30 days. When several insiders buy within a few weeks of each other, analysts speak of a cluster purchase. The last insider purchase was made public on 22 December 2025, 306 days ago. Between a trade and the moment it shows up on SEC (Form 4), the median delay is 2 days. For comparison, the SEC allows two business days to file a Form 4.

Other companies in the same sector with recent insider buying flagged by our signals: Dynavox Group AB and EssilorLuxottica. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.